When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.
Share this @internewscast.com

When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.

“The news wasn’t good,” the widowed grandmother of two from Scone in regional NSW told 9news.com.au.

When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.
Wendy Clift was diagnosed with breast cancer in 2007. (Supplied)

Just days later, she had a mastectomy, followed by more treatment.

While it was successful in keeping her in remission for a few years, the cancer has now returned and it has spread.

However, Clift, now 72, was invited to be part of a new Australian drug trial.

It’s hoped it could help patients with a certain kind of breast cancer live longer.

The DIAmOND clinical trial indicated that introducing dual immunotherapy alongside existing treatments might be beneficial for some patients suffering from advanced HER2-positive breast cancer.

Clift said her cancer appears to be “pretty stable” after the trial earlier this year, which she did at Lake Macquarie Private Hospital.

Some of the cancerous lumps she had have even disappeared, though she doesn’t know if that’s due to the new drug combination.

Clift said she didn’t have side effects.

She said taking part in the trial was less about her and more to help future patients.

“I’m just prepared because whatever happens to me is neither here nor there, but hopefully in years to come it’ll help somebody else,” she said.

Immunotherapy is a treatment that uses a person’s immune system to treat certain cancers.

When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.
Wendy Clift, pictured with son Joshua and grandchildren Florence and Arthur, says she just wants to help future cancer patients. (Supplied)

The other drug used alongside this in the trial was trastuzumab, commonly known as Herceptin.

The trial focused on determining whether the combination could extend the period during which cancer remained controlled in patients with advanced conditions that had developed resistance to trastuzumab.

Results differed depending on the kind of cancer each of the 68 trial patients had.

Some had a response rate of up to 63 per cent, while for other kinds it was 27 per cent.

Some patients saw their cancer controlled for more than two years.

The combination of drugs has been given previously to people with lung cancer.

Professor Sherene Loi developed and led the trial, which was conducted by the research organisation Breast Cancer Trials.

“The encouraging findings imply that pairing new immunotherapy treatments with trastuzumab could provide a new treatment avenue for those with treatment-resistant HER2-positive breast cancer,” Loi stated.

“These findings provide a compelling case for further exploration and how we can best integrate this treatment combination into clinical practice.”

What is HER2-positive breast cancer?

HER2-positive breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2).

However, it often responds well to specific treatments.

Around 15-20 per cent of all types of breast cancers are HER2-positive.

It is more common in younger, pre-menopausal women.

Share this @internewscast.com
You May Also Like
A desperate search continued today for the missing remains of alleged murder victim Julian Story.

Search Ongoing for Missing Remains Following Reality TV Star’s Murder Charge

Warning: This story contains content some readers may find distressing. A desperate…
Customer loyalty is big business for Australian retailers.

Upcoming Changes to Your Wallet Starting This Tuesday

With the new financial year almost upon us, some of Australia’s biggest…

“Critical Alert: Australian Schools Warned About Apps That Can Undress Images”

This article includes mentions of technology-facilitated sexual violence. Australian schools are being…
People gather next to a car that was damaged in an Israeli airstrike in Nabatieh town, south Lebanon, Friday, June 27, 2025. (AP Photo/Mohammed Zaatari)

Israeli Strikes on Southern Lebanon Result in One Dead and Eleven Injured

Israel’s air force launched forceful airstrikes on mountainous regions overlooking a city…

The Influence of Seasons and Weekdays on Sleep Patterns

New research has highlighted how external factors, such as day, season, and…

The Global Fascination with Australia’s ‘Mushroom Murder’ Trial

Recently, the regional Victorian town of Morwell has gained global attention. Patterson…
a male taking money out of the valet.

Increased Salaries, Improved Parental Leave, and Enhanced Superannuation: Upcoming Changes on July 1

The lives of millions of Australians are going to change next week.…
A police officer is decorated with Taylor Swift bracelets while guarding the city centre in Vienna on August 8, 2024.

Accomplice in Alleged Plot to Attack Taylor Swift Concerts Charged in Germany

Earlier this month, a Berlin court received an indictment against a young…

“Australia Designates ‘Terrorgram’ as a Terrorist Organization: A Notorious Group-Chat Linked to Malicious Activities”

The Australian federal government has officially recognized the white supremacist network Terrorgram…

Sussan Ley Claims She’s a Feminist: Is the Term Still Controversial in the Liberal Party?

Opposition leader Sussan Ley made history this May to become the first…
UK Singer Lewis Capaldi has made an emotional return to the iconic Glastonbury Music festival after taking two years off due to his struggle with tourettes syndrome.

UK Singer Triumphantly Returns to Iconic Festival After Battling Health Issues

UK singer Lewis Capaldi has made a heartfelt comeback to the legendary…
Victoria Police Chief Commissioner Mike Bush spoke to members of the force during his first day at the Victoria Police Academy in Melbourne

State’s New Police Chief Issues Stark Warning Following Surge in Crime

Mike Bush is under no illusion about the challenges that confront him…